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Purpose. To explore the safety and eﬃcacy of gemcitabine and docetaxel (GEMDOC) in previously treated patients with recurrent
or metastatic squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods. Patients with advanced SCCHN
previously pretreated with one or two lines of palliative chemotherapy were treated with gemcitabine and docetaxel until disease
progression. Results. Thirty-six patients were enrolled, and 29 were response evaluable. 16 (55%) experienced clinical beneﬁt
(response or stable disease). Six (21%) patients achieved partial response (PR), none achieved complete response (CR), and the
overall response rate (ORR) was 21% (95% CI: 0.10–0.38). Ten (28%) patients had stable disease. The median response duration
(RD) for the 6 PR patients was 3.2 months (80% CI: 2.0–6.1 months). Median overall survival was 4.2 months (95% CI: 2.4–
7.0 months). Among the 33 treated patients: 13 (39%) patients had grade 3-4 anemia, 10 (30%) had grade 3-4 neutropenia.
Conclusion. The study drugs were relatively safe, and the clinical beneﬁt (PR + SD) rate was 55%. However, the eﬃcacy objective
for this regimen was not met. Given the good safety proﬁle, further investigation of this regimen with the addition of a targeted
agent may lead to better eﬃcacy.
1.Introduction
Patients with squamous cell carcinoma of head and neck
(SCCHN) who had disease recurrence after primary surgery
or chemoradiation therapy or who present with metastatic
disease usually have a poor prognosis [1] .T h er o l eo f
chemotherapy in this setting is palliative, complete response
is rare, and duration of response is short.
Single-agent docetaxel was previously evaluated in four
phase II studies involving approximately 160 patients with
metastatic or recurrent SCCHN. The overall response rates
observed in these studies ranged from 21% to 42% [2–5].
The principal toxicity reported in these studies was grade 3
and 4 neutropenia. Based on these phase II studies, single-
agent docetaxel 75–100mg/m2 IV every 3 weeks was shown
tobeanactiveandgenerallywell-toleratedregimenformeta-
static or recurrent SCCHN.
Docetaxel has also been evaluated as part of a doublet
in combination with cisplatin or 5-ﬂuorouracil (5-FU) in
patients with recurrent or metastatic SCCHN. In phase I/II
trials evaluating the combination of docetaxel and cisplatin
the overall response rates were 33% to 40% [6–8]. Studies
evaluating the combination of docetaxel and 5-FU yielded
responseratesfrom24% to27% [9,10].Ofthetwodoublets,
docetaxel combined with cisplatin appeared to be the more
eﬀe c t i v er e g i m e ni nr e g a r dt ob o t ho b j e c t i v ea n dc o m p l e t e
responses [6–9]. In a phase II study conducted by EORTC,
the response rate to the docetaxel plus cisplatin arm was
86% in patients with chemotherapy and radiation na¨ ıve
disease versus 33% for the pretreated group [7]. As with2 ISRN Oncology
Table 1: Phase II studies of biweekly gemcitabine and docetaxel (GEMDOC).
Author N Tumor type Treatment regimen Toxicity
Galetta et al. [11] 45 NSCLC Gemcitabine 2000mg/m2 q2w e e k s
and docetaxel 50mg/m2
Grade 3 and 4 neutropenia 23%,
Grade 3 and 4 alopecia 34%
Pelegri et al. [12] 36 Breast cancer Gemcitabine 2500mg/m2 q2w e e k s
and docetaxel 65mg/m2 Grade 3 and 4 neutropenia 45%
Syrigos et al. [13] 25 NSCLC Gemcitabine 1000mg/m2 q2w e e k s
and docetaxel 80mg/m2
Anemia 16%, neutropenia 20%, febrile
neutropenia 10%, diarrhea 24%, and
asthenia 64%
Shepard et al. [14] 32 Pancreatic Gemcitabine 2000mg/m2 q2w e e k s
and docetaxel 75mg/m2
No grade 4 toxicity
Grade 3 neutropenia 31%
single-agentdocetaxel,theprimarytoxicityineachserieswas
myelosuppression.
Gemcitabine has shown signiﬁcant activity in a wide var-
iety of solid tumors, including cancers of pancreas [15],
breast [16], lung [17], and ovary [18]. A trial of gemcitabine
in head and neck cancers used a relatively low dose
(800mg/m2) and reported 7 partial responses (11%) in 62
patients [19]. Multiple investigators have evaluated the com-
bination of gemcitabine and docetaxel (GEMDOC) in phase
II clinical trials on biweekly bases. [11–14] Previous phase II
studies of biweekly GEMDOC have included patients with
non-small-cell lung cancer, breast cancer, and pancreatic
cancer and are summarized in Table 1. The doses that we
selected from our previous phase I/II trials experience in
head and neck cancer at our facility were 3000mg/m2 for
gemcitabine and 60mg/m2 for docetaxel.
The biweekly GEMDOC combination is an attractive
r e g i m e ni nt h et r e a t m e n to fa d v a n c e dh e a da n dn e c kc a n c e r
since both agents are active against SCCHN with a low
toxicity proﬁle.Therefore,weconductedthisphaseIIclinical
trial to explore the eﬃcacy and toxicity of the GEMDOC
combination given biweekly for patients previously treated
with recurrent or metastatic SCCHN.
2. Patientsand Methods
2.1. Patients. Patients with recurrent or metastatic histo-
logically proven SCCHN who had received 1 to no more
than 2 prior chemotherapy regimens were eligible. Patients
who received a prior taxane agent or gemcitabine were
not eligible. Patients were required to have at least one
bidimensional measurable disease site, assessed by radiologic
exam performed and documented within 28 days prior
to registration. Additional eligibility criteria included a
treatment-free interval of at least 4 weeks prior to study
entry, and no CNS metastases. Patients must have had a
SWOG performance status of ≤2, adequate hematologic cell
counts (absolute neutrophil count ≥1,500/µL and platelets
≥100,000/µL), and adequate liver and renal function.
The institutional review board of the participating
center approved the study, and all patients provided signed
informed consent.
2.2. Study Design and Treatment. This was a prospective,
phase II evaluation of biweekly doses of gemcitabine and
docetaxel. Treatment was given as gemcitabine 3000mg/m2
IV over 30 minutes followed by docetaxel 60mg/m2 IV
over 60 minutes. Appropriate antiemetics were used as
premedication as well as dexamethasone, either 8mg PO
BID starting one day before each dose of docetaxel for
3 days or as 20mg IV prior to docetaxel infusion [20].
Treatment was repeated every two weeks with appropriate
dose modiﬁcations until disease progression, unacceptable
toxicity, or complete remission plus 4 cycles, whichever
occurredﬁrst.Patientscontinuedtoreceivetreatmentsinthe
absenceofanygrade2orhighertoxicities.Infusionwasgiven
on day 1 of treatment with the appropriate dose adjustment
if absolute neutrophil count was >1,000/µL and platelet
count was >50,000/µL. Treatment delay and dose reductions
for docetaxel and gemcitabine were implemented for grade
3-4 neutropenia, thrombocytopenia, or liver dysfunction.
Patients who failed to achieve hematologic recovery for 3
consecutive weeks or more than 4 weeks for nonhematologic
toxicities were removed from the study.
2.3. On-Study Evaluation. Tumor response was assessed
radiographically with standard methods using RECIST cri-
teria [21] every 4 cycles (approximately 2 months). Toxicity
w a se v a l u a t e db e f o r ee a c hc y c l e .A l lp a t i e n t sw e r ec o n s i d e r e d
(regardless of the number of cycles they received) evaluable
for response.
The best overall response was the best response that was
recorded from the start of treatment until disease progres-
sion. The duration of response was measured from the time
measurement criteria were met for complete response (CR)
orpartialresponse(PR)(whicheverstatuswasrecordedﬁrst)
until the ﬁrst date that recurrence or progressive disease
(PD) was recorded since the treatment started. Duration of
stable disease (SD) was measured from the start of treatment
until the criteria for disease progression were met. Response-
evaluable patients were those who were registered and had
their response evaluated and determined by appropriate
measurements, regardless of the number of chemotherapy
cycles they received. Toxicity-evaluable patients were those
who received chemotherapy or any portion of a cycle
of therapy. Patients were taken oﬀ the study if they had
documented PD, an unacceptable adverse event, patient
decision to withdraw from the study, investigator judgment
to stop treatment, or upon completion of 4 cycles after ﬁrst
documented CR.ISRN Oncology 3
Table 2: Baseline characteristics and clinical variables for all 36
patients.
Characteristic N (%)
Age (years)
Median (range) 60 (46–79)
Sex
Female 10 (28%)
Male 26 (72%)
Race
Caucasian 22 (61%)
African-American 12 (33%)
Other 2 (5%)
Performance status (ECOG)
0 8 (22%)
1 26 (72%)
22 ( 6 % )
Prior chemo-radiotherapy
No 1 (3%)
Yes 35 (97%)
Sites of metastasis
Lung 21 (58%)
Liver 2 (6%)
Other 6 (17%)
Treatment cycles administered
Median (range) 4 (0–24)
Percentages may not sum up to 100 due to rounding.
Multiple sites of metastasis may have occurred in the same patient.
The safety and tolerability of biweekly docetaxel and
gemcitabine were evaluated by clinical laboratory assess-
ments, physical examination, and the frequency and sever-
ity of adverse events. Complete blood counts and serum
biochemical assessments were performed every 2 weeks
throughout the study. The severity of adverse events was
graded according to the Common Toxicity Criteria Version
2.0 of the National Cancer Institute. Serious adverse events
included grade 3-4 hematologic and nonhematologic toxici-
ties. Concurrent illnesses, infections, blood product support,
and antimicrobial therapies were monitored.
2.4. Statistical Methods. This single-institution phase II trial
was planned with a Simon two-stage optimal design [22].
The primary endpoint was complete or partial response (CR
+ PR). We wished to distinguish these regions of the true,
unknown response rate: at most 0.25 versus at least 0.45.
The 2-stage design called for a maximum of 41 response-
evaluable (r-e) patients, 17 in stage 1 and 24 in stage 2. The
design had a type I error of 0.050 and power of 0.803.
For response and toxicity rates, Wilson type 95% con-
ﬁdence intervals (CI) were calculated. Response duration
(RD) was measured from start of best response until relapse.
Patients still in remission were censored as of the date of
their last tumor assessment. Due to the small number of
responders (n = 6), the 80% conﬁdence level was used for
the CI of RD. Time to treatment failure (TTF) was measured
from registration until early discontinuation of treatment,
ﬁrst observation of progressive disease, or death from any
cause, whichever occurred ﬁrst. Patients still on treatment
were censored as of the date of their last tumor assessment.
Time to progression (TTP) was measured from registration
until the date of documented progressive disease. Patients
still progression-free were censored as of the date of their last
tumor assessment. Overall survival (OS) was measured from
registration to the date of death from any cause. Patients still
alive were censored as of the most recent date on which they
were known to be alive. Standard Kaplan-Meier estimates
of the censored RD, TTF, TTP, and OS distributions were
computed. Due to the small sample sizes, survival statistics
(e.g., median, 6 month rate, etc.) were estimated more
conservatively using linear interpolation among successive
event times on the Kaplan-Meier curves [23].
3. Results
3.1. Patient Demographics and Disposition. Thirty-six
patients were enrolled between May 2005 and May 2008.
M e d i a na g ew a s6 0y e a r s( r a n g e :4 6t o7 9y e a r s )( Table 2).
Ten female patients (28%) enrolled. 94% of the patients
had good performance status (0-1). Patients with prior
chemo-radiotherapy were 97%. The most common site of
distant metastasis was lung, in 58% of the patients. The
median number of cycles administered was 4 (range: 0 to 24
cycles). Three patients were registered for the study but did
not receive any chemotherapy or follow up staging studies;
therefore, they are considered neither r-e nor drug toxicity
evaluable. In addition, 4 other patients were considered
not r-e due to lack of follow-up staging studies to assess
response.
3.2. Treatment Eﬃcacy. Patient accrual continued to stage 2
of the study design based on the acceptable safety proﬁle, but
mainly to help deﬁne the true response rate, which appeared
to be lower than predicted. Of the 29 r-e patients, 16 (55%)
experienced clinical beneﬁt (SD or disease response). Six
(21%) patients achieved PR, no patients achieved CR, and
the overall response rate (ORR) was 21% (95% CI: 0.10–
0.38; Table 3). In an intent-to-treat analysis of all 36 patients
enrolled, the ORR was 17% (95% CI: 0.08–0.32). Ten (28%)
patients had SD. The median RD for the 6 responding
patients was 3.2 months (80% CI: 2–6.1).
3.3. Hematologic Toxicity. Biweekly gemcitabine and doc-
etaxel (GEMDOC) was generally well tolerated (Table 3).
There were no treatment-related deaths. Bone marrow sup-
pression was the main toxicity. Thirteen (39%) of the 33
treatedpatientshadgrade3-4anemia,and10(30%)patients
had grade 3-4 neutropenia. Grade 3-4 thrombocytopenia
occurred in only 2 (6%) patients. Only one patient had fe-
brile neutropenia.
Twenty-ﬁve (76%) patients received all treatments with-
out a dose reduction and twenty-seven (82%) patients had
no treatment interruption.4 ISRN Oncology
Table 3: Grade 3-4 toxicity summary statistics for all 33 treated patients.
Grade 3-4 toxicity N Events Point
estimate
95% conﬁdence interval
Anemia 33 13 39% 25% 56%
Neutropenia 33 10 30% 17% 47%
Hyponatremia 33 10 30% 17% 47%
Dehydration 33 3 9% 3% 24%
Fatigue 33 3 9% 3% 24%
Dyspnea 33 3 9% 3% 24%
Pneumonia 33 3 9% 3% 24%
Thrombocytopenia 33 2 6% 2% 20%
Febrile neutropenia 33 1 3% 1% 15%
Tachycardia 33 1 3% 1% 15%
Syncope 33 1 3% 1% 15%
Fluid retention 33 1 3% 1% 15%
Mucositis 33 1 3% 1% 15%
Hyperglycemia 33 1 3% 1% 15%
Constipation 33 1 3% 1% 15%
Anorexia 33 1 3% 1% 15%
Vomiting 33 1 3% 1% 15%
Other nonhematologic toxicity 33 1 3% 1% 15%
02468 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4 2 6 2 8 3 0 3 2 3 4 3 6
Time since registration date (months)
(dashed lines are the 95% conﬁdence limits)
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Figure 1: Kaplan-Meier plot of time to progression (TTP) in 36
patients treated with biweekly gemcitabine and docetaxel. Median
TTP was 2.3 months (95% CI: 1.5–3.8 months). The 3-month TTP
rate was 45% (95% CI: 27–63%). The 6-month TTP rate was 17%
(95% CI: 1–32%).
3.4. Nonhematologic Toxicity. The most common grade 3-
4 nonhematologic adverse event was hyponatremia, which
occurred in 10 (30%) patients (Table 3). Grade 3-4 fatigue,
dehydration, and dyspnea occurred in 3 (9%) patients for
each toxicity. Of note, there were no reports of grade 3-4
neuropathy.
3.5. Time to Treatment Failure, Time to Progression, and
Overall Survival. The median TTF was 2.0 months (95% CI:
Time since registration date (months)
(dashed lines are the 95% conﬁdence limits)
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Figure 2: Kaplan-Meier plot of overall survival (OS) in 36 patients
treated with biweekly gemcitabine and docetaxel. Median OS was
4.2 months (95% CI: 2.4–7.0 months). The 6-month OS rate was
40% (95% CI: 24–56%). The 12-month OS rate was 16% (95% CI:
3–28%).
1.6 to 3.6), and the median TTP was 2.3 months (95% CI:
1.5–3.8; Figure 1). The median OS was 4.2 months (95% CI
= 2.4–7.0; Figure 2).
4. Discussion
In this single-institution phase II trial, patients with recur-
rent or metastatic SCCHN were treated with the biweekly
combinationofgemcitabineanddocetaxel (GEMDOC)afterISRN Oncology 5
the failure of at least one prior chemotherapy regimen.
Of the 29 response evaluable patients only 6 achieved PR
and there was no CR observed. It was concluded that the
sample response rate among the r-e patients (6/29 = 21%)
better supported the null hypothesis that the true, unknown
response rate was at most 25%. However, the clinical beneﬁt
(PR + SD) rate was 55%. One proposed reason for the low
response rate is the type of recurrent disease treated, as
the majority of patients included in this trail had previous
one to two lines of chemotherapy or concurrent chemo-
irradiation with unresectable relapses in the radiation ﬁeld.
The study design excluded metastatic-chemotherapy-na¨ ıve
patients. Median response duration in the 6 responders
was 3.2 months. Median time to treatment failure was 2.0
months, with median survival of 4.2 months (Figure 2).
Biweekly treatment with gemcitabine and docetaxel was
generally well tolerated. The median number of cycles
administered was 4. Bone marrow suppression was the main
toxicity. Ten (30%) patients had grade 3-4 neutropenia, 25
(76%) patients received all treatments without a dose reduc-
tion, and 27 (82%) patients had no treatment interruption.
This trial explored a new potential treatment option in a
bad prognosis group of patients with metastatic or recurrent
SCCHN.
Although the studied treatment regimen was safe, the re-
sponse rate was lower than predicted and the study was
terminated. Docetaxel is a well-established agent in the
treatmentofSCCHN[6–8,24],andprobablytherewasmore
added eﬃcacy by combing it with gemcitabine.
Recent data in recurrent or metastatic SCCHN showed
better treatment eﬃcacy driven from combination chemo-
therapy with cisplatin, 5-ﬂuorouracil, and cetuximab [25].
Future clinical trials in this setting should be based on the
use of doublets, either platinum based or taxane based,
with a targeted agent. Given the good safety proﬁle and the
overall clinical beneﬁt of the biweekly GEMDOC regimen,
further investigation of this combination with the addition
of targeted agents may lead to better eﬃcacy results.
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